This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
22 Apr 2011

Proteon Starts Patient Enrolment for PRT-201 Phase II Study

Proteon Therapeutics has started enrolment for a phase 2 trial for PRT-201, a recombinant human elastase.

US-based Proteon Therapeutics has begun enrolment in a phase 2 clinical trial of its lead product PRT-201 in chronic kidney disease (CKD) patients undergoing surgery for arteriovenous fistula (AVF) creation in preparation for haemodialysis.

 

PRT-201 is a recombinant human elastase, which is being studied for its ability to improve AVF and arteriovenous graft (AVG) outcomes in patients requiring chronic hemodialysis.

 

The second phase of the study follows the successful completion of a double-blind, placebo-controlled phase 1/2 study involving 66 AVF patients.

 

Under an agreement signed in 2009, pharmaceutical company Novartis will receive the results of the second part of the study

Related News